Translation of immunosuppressive strategies from animal models of cGVHD into clinical trials
| Main conclusion from the mouse model of cGVHD . | Reference . | Clinical trial . | Reference . |
|---|---|---|---|
| BTK inhibition reduces cGVHD in mice (2014) | 134 | BTK inhibition reduces cGVHD in patients (2016). Phase 1b/2 study | 112 |
| IL-2 is critical for Treg expansion, activity, and survival during GVHD (2004, 2006) | 41,131 | Exogenous IL-2 increases Treg numbers and improves disease in patients with cGVHD (2011). Phase 1/2 study | 114 |
| B cells play a central role in the pathogenesis of cGVHD (2006) | 115 | The B-cell–depleting antibody rituximab is effective in patients with cGVHD. Retrospective analysis (2003); phase 1/2 study (2006) | 116,117 |
| JAK1/2 inhibition reduces cGVHD in the mouse (2015, Supplemental Figures) | 85 | JAK1/2 inhibition reduces cGVHD in patients refractory to multiple therapies (2015). Retrospective analysis | 85 |
| Syk inhibition reduces cGVHD in the mouse (2014, 2015) | 124,125,132 | Open clinical trials for Syk inhibitors (fostamatinib, entospletinib) (2016) | 135 |
| Main conclusion from the mouse model of cGVHD . | Reference . | Clinical trial . | Reference . |
|---|---|---|---|
| BTK inhibition reduces cGVHD in mice (2014) | 134 | BTK inhibition reduces cGVHD in patients (2016). Phase 1b/2 study | 112 |
| IL-2 is critical for Treg expansion, activity, and survival during GVHD (2004, 2006) | 41,131 | Exogenous IL-2 increases Treg numbers and improves disease in patients with cGVHD (2011). Phase 1/2 study | 114 |
| B cells play a central role in the pathogenesis of cGVHD (2006) | 115 | The B-cell–depleting antibody rituximab is effective in patients with cGVHD. Retrospective analysis (2003); phase 1/2 study (2006) | 116,117 |
| JAK1/2 inhibition reduces cGVHD in the mouse (2015, Supplemental Figures) | 85 | JAK1/2 inhibition reduces cGVHD in patients refractory to multiple therapies (2015). Retrospective analysis | 85 |
| Syk inhibition reduces cGVHD in the mouse (2014, 2015) | 124,125,132 | Open clinical trials for Syk inhibitors (fostamatinib, entospletinib) (2016) | 135 |